Dose Optimization and Pharmacogenomic Testing in Pancreatic Cancer Treatment
Midhun Malla, MD
Michael A. Morse, MD, FACP, MHS
Benjamin Leon Musher, MD
Janie Y. Zhang, MD
Rahul Gosain, MD, MBA
Rohit Gosain, MD
Key Points
- Early toxicity management and patient education are essential components of pancreatic cancer care.
- Dose reductions can improve tolerability without necessarily compromising efficacy.
- DPYD testing is increasingly incorporated into routine practice before fluoropyrimidine therapy.
- Pharmacogenomic testing may help personalize chemotherapy dosing and reduce severe toxicities.
At a Clinical Insights discussion coinciding with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Midhun Malla, MD, of the University of Alabama; Michael A. Morse, MD, FACP, MHS, of Duke Cancer Center; Benjamin Leon Musher, MD, of Baylor College of Medicine; and Janie Y. Zhang, MD, of the University of Pittsburgh, joined cohosts Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, for a review of toxicity management and pharmacogenomic testing in metastatic pancreatic adenocarcinoma.
Dr. Musher highlighted the importance of proactive patient education before treatment initiation. Although triplet regimens such as modified FOLFIRINOX (5-fluorouracil [5-FU]/leucovorin, irinotecan, and oxaliplatin) and NALIRIFOX (liposomal irinotecan, 5-FU/leucovorin, and oxaliplatin) are generally associated with greater gastrointestinal toxicity, gemcitabine plus nab-paclitaxel is frequently associated with hematologic toxicities, fatigue, myalgias, and alopecia. He advocated for aggressive supportive care measures, including prophylactic antiemetics, growth factor support when appropriate, and close follow-up during the first treatment cycle. Early intervention can often prevent emergency department visits, treatment interruptions, and unnecessary hospitalizations.
The discussion also addressed dose-modification strategies. Dr. Musher noted that many oncologists routinely initiate therapy at reduced doses rather than administering full protocol doses, particularly in older adults or patients with borderline performance status. Emerging analyses from NAPOLI 3 suggest that dose modifications do not necessarily compromise outcomes and may even improve treatment duration by enhancing tolerability. Thoughtful dose adjustment represents an important component of personalized oncology care rather than a sign of treatment failure, the experts said.
Pharmacogenomic testing generated significant discussion. Dr. Malla reviewed the growing adoption of DPYD testing following recent FDA label updates for fluoropyrimidines. Identifying patients with reduced dihydropyrimidine dehydrogenase activity can help prevent severe fluoropyrimidine-related toxicities. UGT1A1 testing may also provide useful information for irinotecan-containing regimens, although its clinical impact appears less pronounced with the lower liposomal irinotecan doses used in NALIRIFOX. The panel agreed that proactive testing and individualized dose selection can improve treatment safety while maintaining therapeutic effectiveness.